ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / EOCN / financials
ERNA (33) CMND (47) SXTP (38) ONCO (30) ⌘ Pro Terminal →

Eocene Ltd. (EOCN) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$2.87 -7.54% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.83

Eocene Ltd. (EOCN) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $3.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EOCN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EOCN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Eocene Ltd. (NASDAQ: EOCN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $2.87 (-7.54% 1D, market cap $3.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, EOCN ranks #664 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EOCN compare to ERNA and CMND in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EOCN carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ERNA (Ernexa Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $3.2M) and CMND (Clearmind Medicine Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $3.2M). Among the 5-stock peer group, EOCN leads on earnings multiple (N/A) while EOCN leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EOCN?
▼

Per EOCN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001595353), Eocene Ltd. generated $7.8M in revenue (+0.7% YoY), -$10.3M in net income, and -$6.3M in free cash flow against $18.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.83 (-1.55%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (8)Whales (3)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.8% Base Target
$13 Bull$3 Base$2 Bear
📬 FREE EOCN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EOCN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY EOCN SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
42
Grade D$3.16-2.8% Next Q
Q2 (-2Q)
39
Grade E$3.07+0.3% Next Q
Q3 (-1Q)
37
Grade E$3.08-6.8% Next Q
Current
34
Grade E$2.87-8.7% Hist 90D α
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a EOCN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While EOCN currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.53) and Max Pain ($3.01) forces dealer call-delta covering toward $12.94.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EOCN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “EOCN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How EOCN Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$7.8MGross Profit $4.1M (52%)Cost of Sales $3.8MOp Profit $0 (0%)OpEx (R&D/SG&A) $4.1MNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow
FY23
Rev $31.1M
FY24
Rev $7.8M
FY25
Rev $7.8M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$7.8M52%0%-$10.3M-$6.3M-35%
FY 2024$7.8M52%0%-$7.5M-$5.9M-35%
FY 2023$31.1M46.7%0%-$6.9M-$6.1M-35%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EOCN)

  • ✓Walkthrough of EOCN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
EOCN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -38.94%▼ DESCENDING CHANNEL
2026-11-03O $3.22H $3.22L $2.87C $2.87VOL 3.1K
RES: $4.60SUP: $1.90SMA50: $3.53SMA200: $4.56
$8.79$7.04$5.29$3.54$1.79RES $4.60SUP $1.90$2.872026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EOCN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EOCN Butterfly Map → + Track EOCN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +0.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on EOCN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EOCN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for EOCN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EOCN)

Health Care Rank #664 of 1015 ⚔️ ERNA vs EOCN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EOCN vs. ERNA, CMND, SXTP, ONCO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Eocene Ltd. (EOCN) ranks #664 by composite RQD confidence (34/100, grade E) and #973 by equity capitalization ($3.2M). Within this direct 5-issuer industry benchmark cohort, EOCN leads on earnings valuation at N/A trailing P/E, while EOCN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CMND currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with EOCN at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
EOCN ACTIVE
Eocene Ltd.
E 34/100 — — -35.0% -7.54% $3.2M Benchmark Subject
ERNA
Ernexa Therapeutics Inc.
E 33/100 — — -35.0% -1.01% $3.2M /erna-vs-eocn →
CMND
Clearmind Medicine Inc.
D 47/100 — — — -1.27% $3.2M /cmnd-vs-eocn →
SXTP
60 Degrees Pharmaceuticals Inc.
D- 38/100 — 22.3% -35.0% -3.65% $3.3M /sxtp-vs-eocn →
ONCO
Onconetix Inc.
E 30/100 — 77.6% -35.0% -3.24% $3.3M /onco-vs-eocn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001595353 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Eocene Ltd. (EOCN) reported GAAP revenue of $7.8M (+0.7% vs. FY2024 revenue of $7.8M , and -74.8% cumulative change since FY2023) , GAAP net income of -$10.3M, operating cash flow of -$6.3M, and free cash flow of -$6.3M (-7.4% YoY). On the balance sheet, EOCN closed FY2025 with $18.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $7.8M -$10.3M -$6.3M -$6.3M $18.6M —
FY2024 (FY) 2024-12-31 $7.8M -$7.5M -$5.9M -$5.9M $18.5M —
FY2023 (FY) 2023-12-31 $31.1M -$6.9M -$6.1M -$6.1M — —

3. EOCN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EOCN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Eocene Ltd. (NASDAQ: EOCN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $2.87 (-7.54% 1D, market cap $3.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, EOCN ranks #664 in composite RQD confidence.

How does EOCN compare to ERNA and CMND in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EOCN carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ERNA (Ernexa Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $3.2M) and CMND (Clearmind Medicine Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $3.2M). Among the 5-stock peer group, EOCN leads on earnings multiple (N/A) while EOCN leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EOCN?

Per EOCN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001595353), Eocene Ltd. generated $7.8M in revenue (+0.7% YoY), -$10.3M in net income, and -$6.3M in free cash flow against $18.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EOCN trading relative to its 50-day, 200-day, and 52-week technical levels?

EOCN last traded at $2.87 (-7.54% on volume of 9,811 shares), positioning the stock -18.70% below its 50-day simple moving average ($3.53) and -37.06% below its 200-day simple moving average ($4.56). Across its 52-week range of $2.33 to $12.32, EOCN sits at the 5.4% percentile with a 14-day RSI of 44.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.51 to $3.23).

Direct Sub-Reports: EOCN RQD Cockpit EOCN 12M Forecast EOCN Earnings & Move EOCN Dividends & DRIP EOCN Insiders & 13F EOCN Whale Options EOCN Profit Sankey EOCN News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

EOCN — Eocene Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Eocene Ltd. (EOCN) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.87 (-7.54% 1D, market capitalization $3.2M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Eocene Ltd. (EOCN) is a NASDAQ-listed issuer classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry,. — describes its products, customers, or specific revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Eocene Ltd. (EOCN) reported $7.8M in annual revenue (up from $7.8M in FY2024, +0.7% YoY) and -$10.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($31.1M revenue, -$6.9M net income) through FY2025, EOCN scaled operating cash flow to -$6.3M and free cash flow to -$6.3M, backed by $18.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.33 – $12.32 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The supply chain is NONE, with no upstream or downstream dependencies and no sector correlations recorded. — identifies any 2nd-order bottlenecks. A prospective investor should note that the absence of mapped links means the source data cannot show how a pharmaceutical development or commercial milestone would propagate through suppliers or partners.

  • Key Question #1: Can EOCN sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $7.8M and free cash flow of -$6.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is EOCN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

EOCN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Eocene Ltd. (EOCN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to EOCN Debate Forum (3) ↓
🟡 MARKET WIRE TD Economics • 4d ago
The Weekly Bottom Line

<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE5iS3JheUxIbE9wdXkzWk1rUkxjT1p6VTJWeW1uMVpPY1hKYTMtNFF2Qzh1ck5JNTNKVGRSWXlBOWFta2xtZ2tVUTVhT0FlUmpqX1M2UngxLXRZZw?oc=5" target="_blank">The Weekly Bottom L

Read Full Source ↗
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EOCN Bull vs. Bear Conversation Board — What's Your Call at $2.87?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EOCN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on EOCN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $3.66 (+18.1%)
📌 Pinned Debate

The stock trades at a $3.4M market capitalization with a Beta of 1.0 and a 52-week low of $2.33 well below the 52-week high of $12.32,

Here is why I am bullish on EOCN here at $3.10: The stock trades at a $3.4M market capitalization with a Beta of 1.0 and a 52-week low of $2.33 well below the 52-week high of $12.32, leaving room for a rerating if cash generation improves.. Compare EOCN's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $2.94 are getting bought.

ArenaChamp_24 🐂 BULL

@MeanReversion_88 Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $2.63 (-15.2%)
Spot @ $3.10

Free cash flow was negative in every reported period, from -$6.1M in FY 2023 to -$6.3M in FY 2025, with ROIC at -35% and cash falling f

Free cash flow was negative in every reported period, from -$6.1M in FY 2023 to -$6.3M in FY 2025, with ROIC at -35% and cash falling from $4.7M to $4.0M.. Look at the math on EOCN: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $2.73 before getting long.

LIVE TAPE